<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01099085</url>
  </required_header>
  <id_info>
    <org_study_id>2008-12-019</org_study_id>
    <nct_id>NCT01099085</nct_id>
  </id_info>
  <brief_title>Trial of XP (Capecitabine/CDDP) Simvastatin in Advanced Gastric Cancer Patients</brief_title>
  <official_title>Placebo-controlled, Double-blinded Phase III Trial of XP (Capecitabine/CDDP) Simvastatin in Advanced Gastric Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Based on antitumor activity of statin, we designed a phase III study of capecitabine/CDDP
      chemotherapy plus a low-dose simvastatin that is equivalent to cardiovascular dose in
      advanced gastric cancer patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2009</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival of XP ± simvastatin</measure>
    <time_frame>1-year PFS</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">207</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>XP/simvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Capecitabine/cisplatin + simvastatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>XP/placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Capecitabine/cisplatin + placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <description>simvastatin 40 mg qd daily</description>
    <arm_group_label>XP/simvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>XP/placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. histologically or cytologically confirmed diagnosis of gastric adenocarcinoma or
             gastroesophageal junction adenoca (i.e. an adenocarcinoma with &gt; 50% extension in the
             stomach)

          2. patients must present with stage IV disease not amenable to surgery, radiation or
             combined modality therapy with curative intent. Patients previously undergoing local
             treatment (surgery and/or radiation) must have subsequently progressed or recurred

          3. measurable or evaluable disease according to RECIST

          4. age, 18 years or older

          5. ECOG performance status 0 - 2

          6. adequate organ function as defined by the following criteria absolute neutrophil count
             (ANC) ≥ 1,500/ul platelets ≥ 100,000/ul AST/ALT ≤ 2.5 x ULN, ≤ 5.0 x ULN if liver
             involvement Total serum bilirubin ≤ 3.0 mg/dL

          7. signed written informed consent

        Exclusion Criteria:

          1. severe co-morbid illness and/or active infections

          2. pregnant or lactating women

          3. active CNS metastases not controllable with radiotherapy or corticosteroids

          4. active and uncontrollable bleeding from gastrointestinal tract

          5. known history of hypersensitivity to study drugs

          6. patients who are already on statin treatment for hyperlipidemia control (if ≥ 1 year
             interval from the last statin dose, the patient is eligible for study entry)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Samsung Cancer Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2010</study_first_submitted>
  <study_first_submitted_qc>April 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2010</study_first_posted>
  <last_update_submitted>February 15, 2017</last_update_submitted>
  <last_update_submitted_qc>February 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Won Ki Kang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>gastric cancer, unresectable/metastatic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

